Long term outcome of enfortumab vedotin + pembrolizumab in first line locally advanced or metastatic urothelial carcinoma

Olaparib improves disease-free survival in high-risk early-stage HER2-negative breast cancer with BRCA 1/2 mutations

European Cancer Organisation: Time To Act

OncoAlert and ecancer weekly roundup for April 26 - May 3, 2021

UpSwinG: Real-world, non-interventional cohort study on TKI activity in patients with EGFRm NSCLC with uncommon mutations

PIPSeN trial: Olaparib maintenance vs placebo in platinum-sensitive non-small cell lung cancer

Efficacy and early discontinuation predictors in NSCLC patients receiving nivolumab

MRTX9768: a synthetic lethal-based inhibitor designed to bind the PRMT5 MTA complex and target MTAP/CDKN2A-deleted tumours

Anti-tumour activity and tolerability of RMC-4630 as a single agent in patients with RAS-addicted solid cancers

Mechanisms of acquired resistance to KRAS G12C inhibition in cancer

OncoAlert and ecancer weekly roundup for April 19 - 25, 2021

Decolonising palliative care